Lewis M, Löwel H, Stieber J, Engelbrecht R, Hörmann A, John J
GSF-MEDIS-Institut, Neuherberg bei München.
Soz Praventivmed. 1991;36(1):9-17. doi: 10.1007/BF01322295.
The prescriptions of 603 patients who had survived acute myocardial infarction (AMI) for at least one year and were registered from 1 Oct 84 to 31 Dec 86 in the Coronary Event Register of the MONICA project Augsburg were analyzed for the presence of drug-drug interactions with the aid of a computerized drug information system (SMA). Prior to AMI, 59% of patients were treated (average of 2 active substance per patient), 100% were treated on release from hospital (4.5 active substances), and 96% one year after AMI (5.8 active substances). Potential drug-drug interactions were found in 18% of patients before AMI, 65% on discharge from hospital, and 66% one year after AMI. While the potential frequency and severity of interactions are minor on average, prescriptions frequently contain several interactions. Calculations show that at least 5-6% of all prescriptions after AMI will produce interactions, so that drug safety for this high-risk patient group can be enhanced by a drug information system. Beta-blockers are the substance group most frequently involved in potential interactions in AMI patients.
对1984年10月1日至1986年12月31日在奥格斯堡MONICA项目冠心病事件登记处登记的603例急性心肌梗死（AMI）存活至少一年的患者的处方，借助计算机化药物信息系统（SMA）分析药物相互作用情况。在AMI之前，59%的患者接受治疗（平均每位患者使用2种活性物质），100%的患者出院时接受治疗（4.5种活性物质），AMI后一年96%的患者接受治疗（5.8种活性物质）。在AMI之前，18%的患者存在潜在药物相互作用，出院时为65%，AMI后一年为66%。虽然相互作用的潜在频率和严重程度平均较小，但处方中常常包含多种相互作用。计算表明，AMI后所有处方中至少5 - 6%会产生相互作用，因此药物信息系统可提高这一高危患者群体的用药安全性。β受体阻滞剂是AMI患者潜在相互作用中最常涉及的药物类别。
